Andreas Katopodis is the founder of Anaveon. Anaveon has raised $156M in total funding. Latest round: Series B. Based in Basel, Switzerland.
Andreas Katopodis is the co-founder of Anaveon, a Basel-based clinical-stage immuno-oncology biotech. He previously spent 26 years at Novartis and Ciba-Geigy, including a role as Director of Autoimmunity, Transplantation & Inflammation at Novartis Institutes for BioMedical Research. Katopodis also served as a faculty member at the Georgia Institute of Technology for five years.
Full founder directory · Investor directory · Company funding database · Fundraising library